A Cost-Effectiveness Analysis of Alternative Disease Management Strategies in Patients with Crohn's Disease Treated with Azathioprine or 6-Mercaptopurine View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2005-10-01

AUTHORS

Marla C Dubinsky, Eileen Reyes, Joshua Ofman, Chiun-Fang Chiou, Sally Wade, William J Sandborn

ABSTRACT

BACKGROUND: Azathioprine (AZA) is effective for the maintenance of a steroid free remission in Crohn's disease (CD). Thiopurine methyltransferase (TPMT) is important for the metabolism of AZA and influences the production of active AZA metabolites. AZA dose selection based on pharmacogenetic testing of TPMT and metabolite monitoring (MM) may offer a safety and efficacy advantage over traditional dosing strategies. We performed a decision analysis to estimate the potential costs and effectiveness of TPMT screening and MM as disease management strategies for CD. METHODS: Strategies applying TPMT and/or MM to influence treatment decisions were compared to community care (CC). The impact on toxicity minimization and improved time to initial and sustained response was evaluated. A 1-yr model was developed from the third-party payer perspective for mild to moderately chronically active, steroid-treated CD patients. Effectiveness and toxicity defined by time to response CD activity index (CDAI <150, +/- steroids) or time to sustained response (CDAI <150, off steroids x 8 wk) and reduction in leukopenic events, respectively. One- and two-way sensitivity analyses were conducted to determine the effect of varying individual estimates from those used in the base-case analysis. RESULTS: MM, TPMT, and TPMT + MM strategies as compared to CC achieved an earlier time to initial response (18.66, 18.96, and 19.10 vs. 22.41 wk, respectively) and sustained response (39.83, 42.91, and 39.8 vs. 45.36 wk, respectively). The least costly strategy at 1 yr was TPMT ($3,861) and the most costly strategy was CC ($7,142). Each alternative strategy was shown to dominate CC (i.e., less costs and faster time to response or sustained response). The cost-effectiveness rankings were robust to sensitivity analyses on key variables. CONCLUSION: The addition of alternative strategies to CC may improve AZA outcomes and reduce the total cost of care for steroid treated chronically active CD patients, with TPMT being more beneficial for initial response to treatment and MM being more beneficial for sustained response to treatment. More... »

PAGES

ajg2005402

References to SciGraph publications

  • 2000-12-01. Infliximab in Crohn's disease: first anniversary clinical experience in THE AMERICAN JOURNAL OF GASTROENTEROLOGY
  • 2000-02-01. The cost of hospitalization in Crohn's disease in THE AMERICAN JOURNAL OF GASTROENTEROLOGY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1111/j.1572-0241.2005.41900.x

    DOI

    http://dx.doi.org/10.1111/j.1572-0241.2005.41900.x

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1019665075

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/16181376


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Public Health and Health Services", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Azathioprine", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Community Health Services", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cost-Benefit Analysis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Crohn Disease", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Dose-Response Relationship, Drug", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Monitoring", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Genetic Testing", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Health Care Costs", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunosuppressive Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mercaptopurine", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Methyltransferases", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Time Factors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Treatment Outcome", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Pediatrics, Pediatric IBD Center, Cedars-Sinai Medical Center, Los Angeles, CA", 
              "id": "http://www.grid.ac/institutes/grid.50956.3f", 
              "name": [
                "Department of Pediatrics, Pediatric IBD Center, Cedars-Sinai Medical Center, Los Angeles, CA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Dubinsky", 
            "givenName": "Marla C", 
            "id": "sg:person.01312374137.43", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01312374137.43"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Medicine, IBD Center, Mayo Clinic, Rochester Minnesota", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Department of Medicine, IBD Center, Mayo Clinic, Rochester Minnesota"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Reyes", 
            "givenName": "Eileen", 
            "id": "sg:person.01304026372.23", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304026372.23"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Cerner Health Systems, Los Angeles, CA", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Cerner Health Systems, Los Angeles, CA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ofman", 
            "givenName": "Joshua", 
            "id": "sg:person.01315232751.34", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315232751.34"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Cerner Health Systems, Los Angeles, CA", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Cerner Health Systems, Los Angeles, CA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Chiou", 
            "givenName": "Chiun-Fang", 
            "id": "sg:person.01217105721.00", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217105721.00"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Pediatrics, Pediatric IBD Center, Cedars-Sinai Medical Center, Los Angeles, CA", 
              "id": "http://www.grid.ac/institutes/grid.50956.3f", 
              "name": [
                "Department of Pediatrics, Pediatric IBD Center, Cedars-Sinai Medical Center, Los Angeles, CA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Wade", 
            "givenName": "Sally", 
            "id": "sg:person.0617012057.00", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617012057.00"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Cerner Health Systems, Los Angeles, CA", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Cerner Health Systems, Los Angeles, CA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Sandborn", 
            "givenName": "William J", 
            "id": "sg:person.0765241335.25", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0765241335.25"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1111/j.1572-0241.2000.03363.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1029359749", 
              "https://doi.org/10.1111/j.1572-0241.2000.03363.x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1111/j.1572-0241.2000.01779.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1024045039", 
              "https://doi.org/10.1111/j.1572-0241.2000.01779.x"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2005-10-01", 
        "datePublishedReg": "2005-10-01", 
        "description": "BACKGROUND: Azathioprine (AZA) is effective for the maintenance of a steroid free remission in Crohn's disease (CD). Thiopurine methyltransferase (TPMT) is important for the metabolism of AZA and influences the production of active AZA metabolites. AZA dose selection based on pharmacogenetic testing of TPMT and metabolite monitoring (MM) may offer a safety and efficacy advantage over traditional dosing strategies. We performed a decision analysis to estimate the potential costs and effectiveness of TPMT screening and MM as disease management strategies for CD.\nMETHODS: Strategies applying TPMT and/or MM to influence treatment decisions were compared to community care (CC). The impact on toxicity minimization and improved time to initial and sustained response was evaluated. A 1-yr model was developed from the third-party payer perspective for mild to moderately chronically active, steroid-treated CD patients. Effectiveness and toxicity defined by time to response CD activity index (CDAI <150, +/- steroids) or time to sustained response (CDAI <150, off steroids x 8 wk) and reduction in leukopenic events, respectively. One- and two-way sensitivity analyses were conducted to determine the effect of varying individual estimates from those used in the base-case analysis.\nRESULTS: MM, TPMT, and TPMT + MM strategies as compared to CC achieved an earlier time to initial response (18.66, 18.96, and 19.10 vs. 22.41 wk, respectively) and sustained response (39.83, 42.91, and 39.8 vs. 45.36 wk, respectively). The least costly strategy at 1 yr was TPMT ($3,861) and the most costly strategy was CC ($7,142). Each alternative strategy was shown to dominate CC (i.e., less costs and faster time to response or sustained response). The cost-effectiveness rankings were robust to sensitivity analyses on key variables.\nCONCLUSION: The addition of alternative strategies to CC may improve AZA outcomes and reduce the total cost of care for steroid treated chronically active CD patients, with TPMT being more beneficial for initial response to treatment and MM being more beneficial for sustained response to treatment.", 
        "genre": "article", 
        "id": "sg:pub.10.1111/j.1572-0241.2005.41900.x", 
        "inLanguage": "en", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1019809", 
            "issn": [
              "0002-9270", 
              "1572-0241"
            ], 
            "name": "The American Journal of Gastroenterology", 
            "publisher": "Wolters Kluwer", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "10", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "100"
          }
        ], 
        "keywords": [
          "Crohn's disease", 
          "sustained response", 
          "community care", 
          "thiopurine methyltransferase", 
          "CD patients", 
          "third-party payer perspective", 
          "steroid-free remission", 
          "traditional dosing strategies", 
          "CD activity index", 
          "active CD patients", 
          "metabolite monitoring", 
          "metabolism of azathioprine", 
          "initial response", 
          "two-way sensitivity analyses", 
          "base-case analysis", 
          "costly strategy", 
          "cost-effectiveness analysis", 
          "free remission", 
          "efficacy advantage", 
          "dosing strategies", 
          "treatment decisions", 
          "payer perspective", 
          "pharmacogenetic testing", 
          "AZA metabolites", 
          "dose selection", 
          "azathioprine", 
          "activity index", 
          "patients", 
          "disease", 
          "disease management strategies", 
          "care", 
          "alternative strategies", 
          "treatment", 
          "management strategies", 
          "response", 
          "cost-effectiveness ranking", 
          "remission", 
          "mild", 
          "steroids", 
          "outcomes", 
          "toxicity", 
          "sensitivity analysis", 
          "metabolism", 
          "total cost", 
          "screening", 
          "safety", 
          "metabolites", 
          "individual estimates", 
          "strategies", 
          "time", 
          "index", 
          "analysis", 
          "decision analysis", 
          "yr", 
          "testing", 
          "early times", 
          "methyltransferase", 
          "effectiveness", 
          "MM strategy", 
          "reduction", 
          "events", 
          "effect", 
          "maintenance", 
          "monitoring", 
          "addition", 
          "variables", 
          "potential costs", 
          "impact", 
          "production", 
          "key variables", 
          "toxicity minimization", 
          "cost", 
          "alternative disease management strategies", 
          "decisions", 
          "selection", 
          "estimates", 
          "model", 
          "perspective", 
          "advantages", 
          "ranking", 
          "minimization", 
          "active AZA metabolites", 
          "AZA dose selection", 
          "TPMT screening", 
          "steroid-treated CD patients", 
          "leukopenic events", 
          "AZA outcomes"
        ], 
        "name": "A Cost-Effectiveness Analysis of Alternative Disease Management Strategies in Patients with Crohn's Disease Treated with Azathioprine or 6-Mercaptopurine", 
        "pagination": "ajg2005402", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1019665075"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1111/j.1572-0241.2005.41900.x"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "16181376"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1111/j.1572-0241.2005.41900.x", 
          "https://app.dimensions.ai/details/publication/pub.1019665075"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-01-01T18:15", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_412.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1111/j.1572-0241.2005.41900.x"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1111/j.1572-0241.2005.41900.x'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1111/j.1572-0241.2005.41900.x'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1111/j.1572-0241.2005.41900.x'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1111/j.1572-0241.2005.41900.x'


     

    This table displays all metadata directly associated to this object as RDF triples.

    253 TRIPLES      22 PREDICATES      129 URIs      119 LITERALS      21 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1111/j.1572-0241.2005.41900.x schema:about N162dc151e47b46f59d29e116e321908f
    2 N584cfa8e49bb4226813191a11bee33be
    3 N58be561bf8754bf59aadd12aef32dd15
    4 N76fd29dd0dcb46c1b3426be1b0115567
    5 N7ee9bc17214b42098ae441f4c6938e03
    6 N8006c467eda947f9ba177ea2759a7af7
    7 N84adc9d89b6a422e9a828c5bd2eacbfc
    8 N8b416f81a64646459977f86152097bba
    9 Na4fdebc4e5ff4c85a21726faa4178f7e
    10 Nadc3900a69f34362a53f82c4179f790e
    11 Nade2515b240543b59885dca805b8e482
    12 Nb1a07465e8c04dd9889f82a0c8db103e
    13 Nce08a0f78d804f13863b48afa7d9f6cc
    14 Nce5e8b07160d467a8cd92d043e1fb00a
    15 anzsrc-for:11
    16 anzsrc-for:1117
    17 schema:author N2fd8766ec507413b974fd8ea9382d953
    18 schema:citation sg:pub.10.1111/j.1572-0241.2000.01779.x
    19 sg:pub.10.1111/j.1572-0241.2000.03363.x
    20 schema:datePublished 2005-10-01
    21 schema:datePublishedReg 2005-10-01
    22 schema:description BACKGROUND: Azathioprine (AZA) is effective for the maintenance of a steroid free remission in Crohn's disease (CD). Thiopurine methyltransferase (TPMT) is important for the metabolism of AZA and influences the production of active AZA metabolites. AZA dose selection based on pharmacogenetic testing of TPMT and metabolite monitoring (MM) may offer a safety and efficacy advantage over traditional dosing strategies. We performed a decision analysis to estimate the potential costs and effectiveness of TPMT screening and MM as disease management strategies for CD. METHODS: Strategies applying TPMT and/or MM to influence treatment decisions were compared to community care (CC). The impact on toxicity minimization and improved time to initial and sustained response was evaluated. A 1-yr model was developed from the third-party payer perspective for mild to moderately chronically active, steroid-treated CD patients. Effectiveness and toxicity defined by time to response CD activity index (CDAI <150, +/- steroids) or time to sustained response (CDAI <150, off steroids x 8 wk) and reduction in leukopenic events, respectively. One- and two-way sensitivity analyses were conducted to determine the effect of varying individual estimates from those used in the base-case analysis. RESULTS: MM, TPMT, and TPMT + MM strategies as compared to CC achieved an earlier time to initial response (18.66, 18.96, and 19.10 vs. 22.41 wk, respectively) and sustained response (39.83, 42.91, and 39.8 vs. 45.36 wk, respectively). The least costly strategy at 1 yr was TPMT ($3,861) and the most costly strategy was CC ($7,142). Each alternative strategy was shown to dominate CC (i.e., less costs and faster time to response or sustained response). The cost-effectiveness rankings were robust to sensitivity analyses on key variables. CONCLUSION: The addition of alternative strategies to CC may improve AZA outcomes and reduce the total cost of care for steroid treated chronically active CD patients, with TPMT being more beneficial for initial response to treatment and MM being more beneficial for sustained response to treatment.
    23 schema:genre article
    24 schema:inLanguage en
    25 schema:isAccessibleForFree false
    26 schema:isPartOf N072f96e3e2e6428b8269a9b3da0d3dba
    27 N922b4c54d49f49a581b0aa1144e2087e
    28 sg:journal.1019809
    29 schema:keywords AZA dose selection
    30 AZA metabolites
    31 AZA outcomes
    32 CD activity index
    33 CD patients
    34 Crohn's disease
    35 MM strategy
    36 TPMT screening
    37 active AZA metabolites
    38 active CD patients
    39 activity index
    40 addition
    41 advantages
    42 alternative disease management strategies
    43 alternative strategies
    44 analysis
    45 azathioprine
    46 base-case analysis
    47 care
    48 community care
    49 cost
    50 cost-effectiveness analysis
    51 cost-effectiveness ranking
    52 costly strategy
    53 decision analysis
    54 decisions
    55 disease
    56 disease management strategies
    57 dose selection
    58 dosing strategies
    59 early times
    60 effect
    61 effectiveness
    62 efficacy advantage
    63 estimates
    64 events
    65 free remission
    66 impact
    67 index
    68 individual estimates
    69 initial response
    70 key variables
    71 leukopenic events
    72 maintenance
    73 management strategies
    74 metabolism
    75 metabolism of azathioprine
    76 metabolite monitoring
    77 metabolites
    78 methyltransferase
    79 mild
    80 minimization
    81 model
    82 monitoring
    83 outcomes
    84 patients
    85 payer perspective
    86 perspective
    87 pharmacogenetic testing
    88 potential costs
    89 production
    90 ranking
    91 reduction
    92 remission
    93 response
    94 safety
    95 screening
    96 selection
    97 sensitivity analysis
    98 steroid-free remission
    99 steroid-treated CD patients
    100 steroids
    101 strategies
    102 sustained response
    103 testing
    104 thiopurine methyltransferase
    105 third-party payer perspective
    106 time
    107 total cost
    108 toxicity
    109 toxicity minimization
    110 traditional dosing strategies
    111 treatment
    112 treatment decisions
    113 two-way sensitivity analyses
    114 variables
    115 yr
    116 schema:name A Cost-Effectiveness Analysis of Alternative Disease Management Strategies in Patients with Crohn's Disease Treated with Azathioprine or 6-Mercaptopurine
    117 schema:pagination ajg2005402
    118 schema:productId N1a725779f56d46918e62553509d52dc8
    119 N6a92b41d5d95416da0aeba88a2ca2e6e
    120 Ne5e133cd97b54b99a766da138ba644ec
    121 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019665075
    122 https://doi.org/10.1111/j.1572-0241.2005.41900.x
    123 schema:sdDatePublished 2022-01-01T18:15
    124 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    125 schema:sdPublisher N5ab22735d176416bb904bb13cc10d742
    126 schema:url https://doi.org/10.1111/j.1572-0241.2005.41900.x
    127 sgo:license sg:explorer/license/
    128 sgo:sdDataset articles
    129 rdf:type schema:ScholarlyArticle
    130 N072f96e3e2e6428b8269a9b3da0d3dba schema:volumeNumber 100
    131 rdf:type schema:PublicationVolume
    132 N162dc151e47b46f59d29e116e321908f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    133 schema:name Humans
    134 rdf:type schema:DefinedTerm
    135 N1a725779f56d46918e62553509d52dc8 schema:name pubmed_id
    136 schema:value 16181376
    137 rdf:type schema:PropertyValue
    138 N2fd8766ec507413b974fd8ea9382d953 rdf:first sg:person.01312374137.43
    139 rdf:rest N4e13e8da6821452b8121abe6fa2bb611
    140 N4e13e8da6821452b8121abe6fa2bb611 rdf:first sg:person.01304026372.23
    141 rdf:rest Nd71b42172ef44f5cae4d3b1926f6327c
    142 N584cfa8e49bb4226813191a11bee33be schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    143 schema:name Crohn Disease
    144 rdf:type schema:DefinedTerm
    145 N58be561bf8754bf59aadd12aef32dd15 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    146 schema:name Dose-Response Relationship, Drug
    147 rdf:type schema:DefinedTerm
    148 N5ab22735d176416bb904bb13cc10d742 schema:name Springer Nature - SN SciGraph project
    149 rdf:type schema:Organization
    150 N6a92b41d5d95416da0aeba88a2ca2e6e schema:name doi
    151 schema:value 10.1111/j.1572-0241.2005.41900.x
    152 rdf:type schema:PropertyValue
    153 N76fd29dd0dcb46c1b3426be1b0115567 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    154 schema:name Methyltransferases
    155 rdf:type schema:DefinedTerm
    156 N7ee9bc17214b42098ae441f4c6938e03 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    157 schema:name Mercaptopurine
    158 rdf:type schema:DefinedTerm
    159 N8006c467eda947f9ba177ea2759a7af7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    160 schema:name Cost-Benefit Analysis
    161 rdf:type schema:DefinedTerm
    162 N84adc9d89b6a422e9a828c5bd2eacbfc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    163 schema:name Treatment Outcome
    164 rdf:type schema:DefinedTerm
    165 N87b7c7023beb46899c860c306e10923e rdf:first sg:person.01217105721.00
    166 rdf:rest Nc4f4224d3c2c408ebe4a9c04ffe8aabb
    167 N8b416f81a64646459977f86152097bba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    168 schema:name Community Health Services
    169 rdf:type schema:DefinedTerm
    170 N8d02f049a3d84a5b8c6122c3cd3eb79c rdf:first sg:person.0765241335.25
    171 rdf:rest rdf:nil
    172 N922b4c54d49f49a581b0aa1144e2087e schema:issueNumber 10
    173 rdf:type schema:PublicationIssue
    174 Na4fdebc4e5ff4c85a21726faa4178f7e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    175 schema:name Drug Monitoring
    176 rdf:type schema:DefinedTerm
    177 Nadc3900a69f34362a53f82c4179f790e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    178 schema:name Time Factors
    179 rdf:type schema:DefinedTerm
    180 Nade2515b240543b59885dca805b8e482 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    181 schema:name Immunosuppressive Agents
    182 rdf:type schema:DefinedTerm
    183 Nb1a07465e8c04dd9889f82a0c8db103e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    184 schema:name Health Care Costs
    185 rdf:type schema:DefinedTerm
    186 Nc4f4224d3c2c408ebe4a9c04ffe8aabb rdf:first sg:person.0617012057.00
    187 rdf:rest N8d02f049a3d84a5b8c6122c3cd3eb79c
    188 Nce08a0f78d804f13863b48afa7d9f6cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    189 schema:name Azathioprine
    190 rdf:type schema:DefinedTerm
    191 Nce5e8b07160d467a8cd92d043e1fb00a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    192 schema:name Genetic Testing
    193 rdf:type schema:DefinedTerm
    194 Nd71b42172ef44f5cae4d3b1926f6327c rdf:first sg:person.01315232751.34
    195 rdf:rest N87b7c7023beb46899c860c306e10923e
    196 Ne5e133cd97b54b99a766da138ba644ec schema:name dimensions_id
    197 schema:value pub.1019665075
    198 rdf:type schema:PropertyValue
    199 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    200 schema:name Medical and Health Sciences
    201 rdf:type schema:DefinedTerm
    202 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
    203 schema:name Public Health and Health Services
    204 rdf:type schema:DefinedTerm
    205 sg:journal.1019809 schema:issn 0002-9270
    206 1572-0241
    207 schema:name The American Journal of Gastroenterology
    208 schema:publisher Wolters Kluwer
    209 rdf:type schema:Periodical
    210 sg:person.01217105721.00 schema:affiliation grid-institutes:None
    211 schema:familyName Chiou
    212 schema:givenName Chiun-Fang
    213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217105721.00
    214 rdf:type schema:Person
    215 sg:person.01304026372.23 schema:affiliation grid-institutes:None
    216 schema:familyName Reyes
    217 schema:givenName Eileen
    218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304026372.23
    219 rdf:type schema:Person
    220 sg:person.01312374137.43 schema:affiliation grid-institutes:grid.50956.3f
    221 schema:familyName Dubinsky
    222 schema:givenName Marla C
    223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01312374137.43
    224 rdf:type schema:Person
    225 sg:person.01315232751.34 schema:affiliation grid-institutes:None
    226 schema:familyName Ofman
    227 schema:givenName Joshua
    228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315232751.34
    229 rdf:type schema:Person
    230 sg:person.0617012057.00 schema:affiliation grid-institutes:grid.50956.3f
    231 schema:familyName Wade
    232 schema:givenName Sally
    233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617012057.00
    234 rdf:type schema:Person
    235 sg:person.0765241335.25 schema:affiliation grid-institutes:None
    236 schema:familyName Sandborn
    237 schema:givenName William J
    238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0765241335.25
    239 rdf:type schema:Person
    240 sg:pub.10.1111/j.1572-0241.2000.01779.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1024045039
    241 https://doi.org/10.1111/j.1572-0241.2000.01779.x
    242 rdf:type schema:CreativeWork
    243 sg:pub.10.1111/j.1572-0241.2000.03363.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1029359749
    244 https://doi.org/10.1111/j.1572-0241.2000.03363.x
    245 rdf:type schema:CreativeWork
    246 grid-institutes:None schema:alternateName Cerner Health Systems, Los Angeles, CA
    247 Department of Medicine, IBD Center, Mayo Clinic, Rochester Minnesota
    248 schema:name Cerner Health Systems, Los Angeles, CA
    249 Department of Medicine, IBD Center, Mayo Clinic, Rochester Minnesota
    250 rdf:type schema:Organization
    251 grid-institutes:grid.50956.3f schema:alternateName Department of Pediatrics, Pediatric IBD Center, Cedars-Sinai Medical Center, Los Angeles, CA
    252 schema:name Department of Pediatrics, Pediatric IBD Center, Cedars-Sinai Medical Center, Los Angeles, CA
    253 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...